Subependymal giant cell astrocytoma

2 papers

Human trial2

Trial sponsors

Novartis Pharmaceuticals Corporation
Company1 trialPhase 3117 people
Children's Hospital Medical Center, Cincinnati
1 trialPhase 1/228 people

Latest

Lancet14 Nov

Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial

Randomised trial in 117 peoplemTOR inhibitors

The New England Journal of Medicine4 Nov

Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis

Non-randomised trial in 28 peoplemTOR inhibitors